I guess the KOLs are no longer in hiding. So we can put aside all those "I never see pphm or bavi mentioned" comments now. The KOLs seem to be definitely lining up under the pphm and bavi umbrella.
SITC'15, Poster=B357(Bavi+PD-L1/Breast), Senior-Author: Duke's Dr. Herbert K. Lyerly. The Lead(publishing) author is Peregrine's Dr. Michael Gray, but interesting that Dr. Lyerly is listed as the last author (typically the Senior Author), along with 2 other Duke researchers listed as co-authors. Clearly Duke is working with Peregrine on pre-clinical bavituximab cancer I-O combination studies. ...As Johnny Carson would say, “I did not know that.”
2 other Duke scientists are listed as co-authors: * Dr. Takuya Osada (MD/PhD – Duke Cancer Inst. - Hematology, Oncology, Clinical Immunology http://www.researchgate.net/profile/Takuya_Osada2 ) * Dr. Zachary Hartman (PhD) – Duke MC, Section of Applied Therapeutics http://surgery.duke.edu/faculty/details/0281172”My group is also involved in strategies to modulate the immune response to tumors, which involves the use of novel immunotherapeutic strategies & dev. of vaccines to specific oncogenic targets.”
= = = = = = = = = = = = = = SITC'15 Track: “Optimizing Combination Immunotherapy” 11-7-15/Sat./12:45-2:00pm PPHM#2: Poster P357, “Targeting of Phosphatidylserine by Monoclonal Antibodies Augments the Activity of Paclitaxel & anti-pd1/pd-L1 Therapy in the Murine Breast Model E0771” Presenting Author: Michael Gray, PhD (Sr.Scientist, Peregrine Pharmaceuticals) Michael Gray 1, Jian Gong 1, Van Nguyen 1, Takuya Osada 2, Zachary Hartman 2, Jeff Hutchins 1, Bruce Freimark 1, Kim (Herbert K.) Lyerly** 2 ...1=Peregrine Pharmaceuticals, Tustin CA ...2=Duke University, Durham, NC **Dr. Herbert Kim Lyerly: http://surgery.duke.edu/faculty/details/0117267 (Professor of Surgery, Assistant Professor in Immunology, Associate Professor of Pathology, Duke Univ. MC) http://www.immunotherapyofcancer.org/content/pdf/2051-1426-3-S2-P357.pdf INTRODUCTION: The phospholipid lipid phosphatidylserine (PS) normally resides in the inner plasma membrane leaflet in most mammalian cells, including tumor and tumor associated vascular cells. Inducers of cellular stress, such as hypoxia and oxygen radicals encountered in tumors, and treatments by cytotoxic therapies promote PS relocation to the outer leaf of the plasma membrane. In tumors this re-localization allows PS recognition by a number of receptors on myeloid and lymphoid cells in the microenvironment, promoting tumor growth and metastatic disease through the development of an immunosuppressive environment. Currently the PS-targeting antibody bavituximab is being used to treat patients with solid tumors in multiple late-stage clinical trials. Bavituximab’s anti-tumor properties are attributed in part through alleviating PS- receptor mediated immunosuppression and assisting in generating an Fc-FcR mediated pro-inflammatory response. METHODS: Immune competent mice with E0771 induced tumors were administered either paclitaxel, or anti-PD-1/PD-L1 single agent therapy, or in triple combination with PS targeting antibody (ch1N11) to evaluate the efficacy of PS & PD-1/PD-L1 immune checkpoint inhibitors blockade in combination with cytotoxic chemotherapeutics. The levels of PS & PD-L1 expression were also evaluated on E0771 tumor cells following in vitro treatment via FACS analysis. RESULTS: Preliminary results in multiple studies demonstrated differential sensitivity to either paclitaxel, or anti- PD-1/PD-L1 single agent therapy while inclusion of ch1N11 triple combination significantly enhanced anti-tumor efficacy over either single agent therapy. Also, FACs analysis demonstrated induction of PS & PD-L1 levels on E0771 cells following in vitro treatment with paclitaxel, suggesting that combining paclitaxel with PS and PD-1 targeting antibodies will have greater anti-tumor activity in triple combination treatments. No in vivo adverse effects were observed in animals given repeated doses of single or triple combinations. CONCLUSION: These results support combination blockade of PS & PD-1/PD-L1 with paclitaxel to treat breast cancer.
= = = = = = = = = = = = = = = = Nov4-8 2015: “(SITC) Society for Immunotherapy of Cancer 30th Annual Meeting”, Natl-Harbor MD ”The premier destination for scientific exchange, education, and networking in the Cancer Immunotherapy Field” SITC = The Society for Immunotherapy of Cancer http://www.sitcancer.org SITC 2015 Meeting: http://www.sitcancer.org/2015 EXHIBITOR: Peregrine Pharm. - booth #121 (directly across from #120/ASCO & BMY/124; AstraZeneca/108 & DNA/113 are close by) ...Floorplan: http://www.eventscribe.com/2015/sitc/exhibitors/index.asp Pics of PPHM's SITC'15 Booth #121 (Nov4-8 2015) - directly across from #120/ASCO & BMY/124; AstraZeneca/108 & DNA/113 are close by.: http://tinyurl.com/p32rqfn
= = = =PPHM's 2nd Poster at SITC'15 (Nov 4-8 2015:) PPHM#1: Poster P358, “Targeting Phosphatidylserine Synergizes with Immune Checkpoint Blockade by Inducing De Novo Tumor Specific Immunity” Presenting Author: Xianming Huang, PhD (UTSW-MC/Dallas) Xianming Huang 1, Jian Gong 2, Dan Ye 1, Van Nguyen 2, Michael Gray 2, Steven King 2, Jeff Hutchins 2, Rolf Brekken 1, Bruce Freimark 2 ...1 UTSW-MC/Dallas ...2 Peregrine Pharmaceuticals, Tustin CA Direct Link: http://bit.ly/1LS4VYk http://www.immunotherapyofcancer.org/content/pdf/2051-1426-3-S2-P358.pdf
Market Data 
Markets 
AI
